| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 0.5 mg | 0.5 (0.5) | 6 hourly | PO | This is the recomended starting dose. For one week. It is recommended that patients with moderate hepatic impairment start anagrelide therapy at a dose of 0.5 mg/day and be maintained for a minimum of one week with careful monitoring of cardiovascular effects. The dosage increment must not exceed more than 0.5 mg/day in any one-week. To monitor the effect of anagrelide and prevent the occurrence of thrombocytopenia, platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached. |
| 1 mg | 1 (1) | 12 hourly | PO | This can also be the starting dose. For one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose. To monitor the effect of anagrelide and prevent the occurrence of thrombocytopenia, platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached. |
| 0.1 % | 0.1 (0.1) | 24 hourly | Topical | 0.1% may be used with caution in pediatric patients 1 year of age or older. The safety and efficacy of drug use for longer than 3 weeks in this population have not been established. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Anagrelide is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Anagrelide is available. |